The efficacies of the EZH2 inhibitors EPZ-6438 (also known as Tazemetostat) and GSK126 against various cancers, including B-cell lymphoma, have been tested in clinical trials5,12. This evidence concerns the gene EZH2 and B-cell non-Hodgkin lymphoma.